Locations:
Search
Combination therapy may help address underlying disease
Highlighting treatment gaps and challenges in the management of rare condition
Explaining common misconceptions about chimeric antigen receptor therapy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Findings from large database important to inform clinical practice
Offers a new option for patients 60 and older with relapsed/refractory disease
What’s coming up at ASH and beyond
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Advertisement
Advertisement